• Something wrong with this record ?

Screening for Fabry disease in male patients with end-stage renal disease in western France

C. Vigneau, DP. Germain, D. Larmet, F. Jabbour, M. Hourmant, SNOUFY Investigators Group

. 2021 ; 17 (3) : 180-184. [pub] 20210511

Language English Country France

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22004281

CONTEXT: Fabry disease is a rare X-linked genetic disease due to pathogenic variants in the GLA gene. Classic Fabry disease is characterized by glycosphingolipids accumulation in all organs including the kidney, resulting in end-stage renal disease in a subset of male patients. Fabry disease should therefore be considered in the differential diagnosis of patients with unexplained end-stage renal disease. OBJECTIVE: We performed a prospective screening study in Western France to determine the prevalence of Fabry disease in a large population of dialyzed and transplanted patients. PATIENTS AND METHODS: Patients meeting the inclusion criteria (males, 18-70 years with end-stage renal disease of unknown or vascular origin) were selected from the REIN® registry and the CRISTAL® database. Screening on filter papers was performed after patient consent was obtained during either a dialysis session or a transplantation follow-up visit. RESULTS: One thousand five hundred and sixty-one end-stage renal disease male patients were screened and 819 consented (dialysis: n=242; transplant: n=577). One single patient was found with decreased alpha-galactosidase levels <25%. GLA sequencing identified the p.Phe113Leu variant in favor of an unknown superimposed kidney disease responsible for end-stage renal disease since this GLA pathogenic variant is associated with a later-onset cardiac form of Fabry disease with minimal kidney involvement. Family cascade genotyping revealed a previously undiagnosed affected brother. CONCLUSION: The prevalence of Fabry disease in end-stage renal disease patients was 0.12%, questioning the efficacy of this screening strategy with respect to the low prevalence. However, beside the benefit for the patient and his family, the increased awareness of Fabry disease among participating nephrologists may be of interest for future patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004281
003      
CZ-PrNML
005      
20220127145359.0
007      
ta
008      
220113s2021 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.nephro.2021.03.002 $2 doi
035    __
$a (PubMed)33994139
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Vigneau, C $u Inserm, EHESP, IRSET, UMR_S 1085, University of Rennes, CHU de Rennes, 35000 Rennes, France
245    10
$a Screening for Fabry disease in male patients with end-stage renal disease in western France / $c C. Vigneau, DP. Germain, D. Larmet, F. Jabbour, M. Hourmant, SNOUFY Investigators Group
520    9_
$a CONTEXT: Fabry disease is a rare X-linked genetic disease due to pathogenic variants in the GLA gene. Classic Fabry disease is characterized by glycosphingolipids accumulation in all organs including the kidney, resulting in end-stage renal disease in a subset of male patients. Fabry disease should therefore be considered in the differential diagnosis of patients with unexplained end-stage renal disease. OBJECTIVE: We performed a prospective screening study in Western France to determine the prevalence of Fabry disease in a large population of dialyzed and transplanted patients. PATIENTS AND METHODS: Patients meeting the inclusion criteria (males, 18-70 years with end-stage renal disease of unknown or vascular origin) were selected from the REIN® registry and the CRISTAL® database. Screening on filter papers was performed after patient consent was obtained during either a dialysis session or a transplantation follow-up visit. RESULTS: One thousand five hundred and sixty-one end-stage renal disease male patients were screened and 819 consented (dialysis: n=242; transplant: n=577). One single patient was found with decreased alpha-galactosidase levels <25%. GLA sequencing identified the p.Phe113Leu variant in favor of an unknown superimposed kidney disease responsible for end-stage renal disease since this GLA pathogenic variant is associated with a later-onset cardiac form of Fabry disease with minimal kidney involvement. Family cascade genotyping revealed a previously undiagnosed affected brother. CONCLUSION: The prevalence of Fabry disease in end-stage renal disease patients was 0.12%, questioning the efficacy of this screening strategy with respect to the low prevalence. However, beside the benefit for the patient and his family, the increased awareness of Fabry disease among participating nephrologists may be of interest for future patients.
650    12
$a Fabryho nemoc $x komplikace $x diagnóza $x epidemiologie $7 D000795
650    _2
$a lidé $7 D006801
650    12
$a chronické selhání ledvin $x diagnóza $x epidemiologie $x etiologie $7 D007676
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    _2
$a dialýza ledvin $7 D006435
650    _2
$a alfa-galaktosidasa $x genetika $7 D000519
655    _2
$a časopisecké články $7 D016428
700    1_
$a Germain, D P $u Inserm, EHESP, IRSET, UMR_S 1085, University of Rennes, CHU de Rennes, 35000 Rennes, France; French Referral Center for Fabry disease, Division of Medical Genetics, AP-HP Paris Saclay University, University of Versailles, 2, avenue de la source de la Bièvre, 78180 Montigny, France; Second Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic; Faculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia. Electronic address: dominique.germain@uvsq.fr
700    1_
$a Larmet, D $u Department of Nephrology, University of Nantes, 44093 Nantes cedex 01, France
700    1_
$a Jabbour, F $u French Referral Center for Fabry disease, Division of Medical Genetics, AP-HP Paris Saclay University, University of Versailles, 2, avenue de la source de la Bièvre, 78180 Montigny, France
700    1_
$a Hourmant, M $u Department of Nephrology, University of Nantes, 44093 Nantes cedex 01, France
710    2_
$a SNOUFY Investigators Group
773    0_
$w MED00167286 $t Nephrologie & therapeutique $x 1872-9177 $g Roč. 17, č. 3 (2021), s. 180-184
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33994139 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145356 $b ABA008
999    __
$a ok $b bmc $g 1751677 $s 1155430
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 17 $c 3 $d 180-184 $e 20210511 $i 1872-9177 $m Néphrologie & thérapeutique $n Néphrol. thér. $x MED00167286
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options